NCT06275893 - IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 29, 2024

Primary Completion Date

August 15, 2025

Study Completion Date

December 1, 2025

Conditions

Arrhythmogenic Right Ventricular DysplasiaArrhythmogenic Left Ventricular CardiomyopathyArrhythmogenic Right Ventricular Cardiomyopathy 1Arrhythmogenic CardiomyopathyACMARVCPKP2

Interventions

BIOLOGICAL

IC14

recombinant monoclonal antibody directed against cluster of differentiation 14 (CD14) antigen

Trial Locations (2)

44195

Cleveland Clinic, Cleveland

63110

Washington University School of Medicine, St Louis